PMID- 20668713
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20211020
IS  - 1178-203X (Electronic)
IS  - 1176-6336 (Print)
IS  - 1176-6336 (Linking)
VI  - 6
DP  - 2010 Jul 21
TI  - Update on current and emerging treatment options for post-polio syndrome.
PG  - 307-13
AB  - Post-polio syndrome (PPS) refers to the clinical deterioration experienced by 
      many polio survivors several decades after their acute illness. The symptoms are 
      new muscle weakness, decreased muscle endurance, fatigue, muscle pain, joint 
      pain, cold intolerance, and this typical clinical entity is reported from 
      different parts of the world. The pathophysiology behind PPS is not fully 
      understood, but a combination of distal degeneration of enlarged motor units 
      caused by increased metabolic demands and the normal aging process, in addition 
      to inflammatory mechanisms, are thought to be involved. There is no diagnostic 
      test for PPS, and the diagnosis is based on a proper clinical workup where all 
      other possible explanations for the new symptoms are ruled out. The basic 
      principle of management of PPS lies in physical activity, individually tailored 
      training programs, and lifestyle modification. Muscle weakness and muscle pain 
      may be helped with specific training programs, in which training in warm water 
      seems to be particularly helpful. Properly fitted orthoses can improve the 
      biomechanical movement pattern and be energy-saving. Fatigue can be relieved with 
      lifestyle changes, assistive devices, and training programs. Respiratory 
      insufficiency can be controlled with noninvasive respiratory aids including 
      biphasic positive pressure ventilators. Pharmacologic agents like prednisone, 
      amantadine, pyridostigmine, and coenzyme Q10 are of no benefit in PPS. 
      Intravenous immunoglobulin (IVIG) has been tried in three studies, all having 
      positive results. IVIG could probably be a therapeutic alternative, but the 
      potential benefit is modest, and some important questions are still unanswered, 
      in particular to which patients this treatment is useful, the dose, and the 
      therapeutic interval.
FAU - Farbu, Elisabeth
AU  - Farbu E
AD  - Neurocenter and National Competence Center for Movement Disorders, Stavanger 
      University Hospital, Stavanger, Norway.
LA  - eng
PT  - Journal Article
DEP - 20100721
PL  - New Zealand
TA  - Ther Clin Risk Manag
JT  - Therapeutics and clinical risk management
JID - 101253281
PMC - PMC2909497
OTO - NOTNLM
OT  - aging
OT  - fatigue
OT  - polio
OT  - survivors
OT  - therapeutics
EDAT- 2010/07/30 06:00
MHDA- 2010/07/30 06:01
PMCR- 2010/07/21
CRDT- 2010/07/30 06:00
PHST- 2010/07/03 00:00 [received]
PHST- 2010/07/30 06:00 [entrez]
PHST- 2010/07/30 06:00 [pubmed]
PHST- 2010/07/30 06:01 [medline]
PHST- 2010/07/21 00:00 [pmc-release]
AID - tcrm-6-307 [pii]
AID - 10.2147/tcrm.s4440 [doi]
PST - epublish
SO  - Ther Clin Risk Manag. 2010 Jul 21;6:307-13. doi: 10.2147/tcrm.s4440.